The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) is launching an investigation into clinics offering unregulated peptide therapies, following reports of misleading health claims. Demand for these experimental treatments has surged in recent years, with sellers and some practitioners marketing them for benefits ranging from anti-aging to faster injury recovery – despite limited scientific evidence.
The Rise of Experimental Peptides
Peptides, short chains of amino acids, are being promoted through injections, often with little to no rigorous human testing. While some peptides occur naturally in the body (like insulin), many marketed for therapeutic purposes remain experimental. The boom in interest coincides with the increased popularity of prescription peptide-based weight loss drugs like semaglutide (Wegovy) and tirzepatide (Mounjaro), but these regulated medications undergo far more stringent testing than the unregulated peptides now flooding the market.
What the Investigation Will Focus On
The MHRA will scrutinize clinics making “medicinal claims” for peptide treatments, as such claims classify the products as regulated medicines under the Human Medicines Regulations 2012. The agency has warned that clinics violating these regulations will face enforcement action. A Guardian investigation found several UK clinics advertising unregulated peptides with unsubstantiated claims on their websites.
One clinic advertised Cortexin for “neuroprotection and cognitive enhancement,” BPC-157 for “tissue repair,” and Thymosin Alpha for “immune function boosting.” These claims were removed after the Guardian flagged them. Another clinic acknowledged the lack of large-scale human trials but still sold peptides with labeled prices and “results durations.”
Clinician Admissions: Experimental Treatments, Limited Evidence
A reporter posing as a patient received advice from a clinic clinician who admitted most peptide research is pre-clinical. The clinician acknowledged the absence of long-term safety data and recommended cycling peptide use (4-8 weeks off every 2-3 months) to mitigate risks. Despite this, the reporter was encouraged to combine BPC-157 for recovery and MOTS-C for “stress resilience,” with the clinician explaining how BPC-157 aids recovery even without directly improving performance.
The clinician also warned against using BPC-157 if the patient had a family history of cancer, citing concerns about increased blood supply to tumors. MOTS-C was promoted for reducing insulin resistance and boosting energy production. The MHRA is investigating these claims.
Regulatory Gray Areas and Unregulated Markets
The clinic defended its practices, stating it “clearly explained that the peptides discussed are not licensed medicines” and that evidence is largely pre-clinical. It also noted a significant number of individuals already obtain peptides through unregulated channels, where quality control and safety screenings are absent.
The MHRA defines a medicinal product broadly, including substances presented as preventing or treating disease, correcting physiological functions, or making medical diagnoses. The agency disregards “research purposes” claims if they are used to circumvent regulations.
“We disregard claims that products are for ‘research purposes’ if it is clear that such claims are being used as an attempt to avoid medicines regulations.”
The investigation highlights the need for stronger enforcement against clinics making unsubstantiated health claims. The unregulated peptide market poses risks to consumers, as many treatments lack rigorous safety and efficacy data. The MHRA’s action aims to protect public health by ensuring that any substance marketed for medical purposes undergoes proper regulatory scrutiny.
